Associate Professor, Neurology, University of Maryland School of Medicine
Neurology
Dr. Horea Rus, MD
|
|
Give Review
Horea practices Neurology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Doctor Horea Rus, MD is a published doctor as well. He has 92 publications published. The latest was: Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. He is registered with Medicare and accepts Medicare payments.
Publications
- CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model.
- RGC-32 is a novel regulator of the T-lymphocyte Cell cycle.
- Role of SIRT1 in autoimmune demyelination and neurodegeneration.
- SIRT1 is decreased during relapses in patients with multiple sclerosis.
- Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in Cancer.
- Dual role of Response gene to complement-32 in multiple sclerosis.
- IL-21 Promotes Lupus-like Disease in Chronic Graft-versus-Host Disease through Both CD4 T Cell- and B Cell-Intrinsic Mechanisms.
- Membrane attack by complement: the assembly and biology of terminal complement complexes.
- C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte Cell cycle activation and dedifferentiation.
- FLT-3 expression and function on microglia in multiple sclerosis.
- Epigenetic modifications induced by RGC-32 in colon Cancer.
- Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
- TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proInflammatory effects.
- Response gene to complement 32 is required for C5b-9 induced Cell cycle activation in endothelial Cells.
- RGC-32 mediates transforming growth factor-beta-induced epithelial-mesenchymal transition in human renal proximal tubular Cells.
- Complement C5 regulates the expression of insulin-like growth factor binding proteins in Chronic experimental allergic encephalomyelitis.
- Role of response gene to complement 32 in Diseases.
- B-Cells and humoral immunity in multiple sclerosis. Implications for therapy.
- Dendritic Cells are abundant in non-lesional gray matter in multiple sclerosis.
- Neuroinflammatory response of the choroid Plexus epithelium in fatal diabetic ketoacidosis.
- The complement system in central nervous system Diseases.
- Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
- C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
- Oligodendrocyte Cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement.
- Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central Nervous system.
- C5b-9-induced endothelial Cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.
- JNK1 activation mediates C5b-9-induced P0 mRNA instability and P0 gene expression in Schwann Cells.
- Complement activation in diabetic ketoacidosis Brains.
- C5b-9 terminal complex protects oligodendrocytes from apoptotic Cell death by inhibiting caspase-8 processing and up-regulating FLIP.
- Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial Cell proliferation.
- The role of the complement System in innate immunity.
- The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis Brain.
- C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
- Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft-vs.-host Disease.
- Overexpression of RGC-32 in colon Cancer and other tumors.
- The role of c5b-9 terminal complement complex in activation of the Cell cycle and transcription.
- The role of complement activation in atherosclerosis.
- Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.
- Effects of membrane attack complex of complement on apoptosis in experimental autoimmune encephalomyelitis.
- C5b-9 terminal complement complex assembly on apoptotic Cells in human arterial wall with atherosclerosis.
- Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes.
- Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.
- Association of complement inhibitors with connective tissue matrix in atherosclerotic lesions.
- Pathogenic T Cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways.
- RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle Cells into S-phase.
- Role of the C5b-9 complement complex in Cell cycle and apoptosis.
- Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall.
- Binding of a protein to an AU-rich domain of tumour necrosis factor alpha mRNA as a 35 kDa complex and its regulation in primary rat astrocytes.
- Sublytic complement attack induces Cell cycle in oligodendrocytes.
- Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes.
- Decrease of alpha 1-antitrypsin during hemodialysis.
- Immunologic alterations associated with Chronic hemodialysis.
- Immune deposits in human aortic atherosclerotic wall.
- [Activation of the complement System during chronic hemodialysis].
- [Activation of the complement System in the course of chronic hemodialysis].
- Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall.
- Plasma fibronectin in peripheral arterial Disease.
- Increased level of plasma factor VIII-related antigen in peripheral arterial Disease.
- Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
- Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.
- Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.
- Immunohistochemical detection of the terminal C5b-9 complement complex in children with glomerular Diseases.
- Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque.
- Presence of C5b-9 complement complex and S-protein in human myocardial areas with necrosis and sclerosis.
- Immunohistochemical localization of the terminal C5b-9 complement complexes associated to S-protein and macrophage immunoreactive deposits in human damaged myocardial ...
- Determination of antibodies to nuclear antigens with special reference to dsDNA using indirect immunoperoxidase.
- C5b-9 deposition in children with glomerular Diseases.
- Co-localization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls.
- Lupus anticoagulant and transient severe bleeding tendency in a girl aged nine years.
- Plasma fibronectin and factor XIII in nephrotic Syndrome.
- [The complement System: its biology and implications in pathology].
- Detection of antinuclear antibodies by indirect immunoperoxidase using HEp-2 Cell line.
- The relationship between macrophages and C5b-9 complement complexes in human atherosclerosis.
- Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis.
- Cells carrying C5b-9 complement complexes in human atherosclerotic wall.
- [The carcinoembryonic antigen (CEA)--its biology and implications in pathology].
- [Heterophile antibodies].
- Factor XIII, fibronectin and clot lysis in hyperlipidemia.
- [The isolation of anti-carcinoembryonic antigen (CEA) immunoglobulins and their use in immunocytochemical and immunoenzyme (ELISA) technics].
- Isolation of anti-carcinoembryonic antigen (CEA), specific immunoglobulins and their use in immunocytochemical and enzyme-immunoassays (ELISA).
- Tissue-type plasminogen activator (t-PA) and dilute blood clot lysis time in nephrotic patients.
- Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall.
- Activation of the human terminal complement pathway in atherosclerosis.
- Protein distribution across the human atherosclerotic wall with reference to immunoglobulins and complement components.
- Immunoglobulins and complement components in human aortic atherosclerotic intima.
- [The role of endothelial Cells in inflammation and immunity].
- Hemostatic variables in nephrotic patients.
- Tumor necrosis factor-alpha in human arterial wall with atherosclerosis.
- Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall.
- Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle Disease virus.
- Persistent complement activation on tumor cells in breast Cancer.
Schools
Institutul De Medicina Si Farmacie
St Agnes Hospital
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Autonomic Disorders
- View All
Doctors Specialties
- Neurology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Select
- Amerigroup (Wellpoint)
- Amerihealth
- Blue Card PPO
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Geisinger Health Plan
- Golden Rule
- GEHA
- Choice Care PPO
- Kaiser Permanente
- Maryland Physicians Care
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Simplifi
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Maryland -
Iuliu Hatieganu University of Medicine and Pharmacy
Hospital
-
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1881701266 | |
| NPPES Provider LastName | RUS | |
| NPPES Provider FirstName | HOREA | |
| NPPES Provider ZIPCode | 212011606 | |
| NPPES Provider State | MD | |
| Specialty Description | Neurology | |
| Total Claim Count | 518.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881701266 |
| Last Name Of The Provider | RUS |
| First Name Of The Provider | HOREA |
| View All |
Similar Doctors
|
|
Dr. Andrew Mammen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua A. Kornbluth, MD |
|
|
Dr. Steven L. Strauss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Weiner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lindsay A. Zilliox, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barney J. Stern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Braeme S. Glaun, MD |
|
|
Dr. Karen G. Hirsch, MD |
|
|
Dr. James J. Vornov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel R. Gold, MD |
|
|
Dr. William J. Herring, MD |
|
|
Dr. Shirish S. Satpute, MD
This Doctor is OpenDoctor Recommended.
|